5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
5 α还原酶基因型,种族前列腺癌风险
基本信息
- 批准号:2908927
- 负责人:
- 金额:$ 37.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-09-30 至 2004-05-31
- 项目状态:已结题
- 来源:
- 关键词:African American Asian Americans androstane compound cancer risk clinical research enzyme activity gene mutation genetic polymorphism genetic susceptibility genotype human genetic material tag human subject male neoplasm /cancer epidemiology neoplasm /cancer genetics neoplastic process nucleic acid sequence prostate neoplasms racial /ethnic difference steroid hormone metabolism testosterone testosterone 5 alpha reductase
项目摘要
DESCRIPTION: (Adapted from the Investigator's Abstract) Prostate cancer is
currently the most common cancer among American men. Regulation of prostatic
cell growth is largely controlled by androgens including especially
dihydrotestosterone (DHT). This compound is synthesized from the male hormone
testosterone by the enzyme 5-alpha reductase which is encoded in the prostate
by the SRD5A2 gene. The etiology of prostate cancer appears to include
increased steroid 5-alpha reductase activity particularly across racial/ethnic
groups which are at very different risk for prostate cancer, such as high-risk
African-Americans and lower risk Asians, the two extreme groups for risk. We
have identified and characterized genetic variability in the SRD5A2 gene among
various racial/ethnic groups in the US and between prostate cancer cases and
controls. These investigations made use of a large multiethnic cohort in Los
Angeles and Hawaii. We propose to build on and expand our studies of the SRD5A2
gene and prostate cancer by epidemiologic, genetic and biochemical methods. It
is our overall hypothesis that genetic variation at the SRD5A2 locus plays a
significant role in predisposition to and progression of prostate cancer and in
explaining the racial/ethnic variation of risk. To this end, we intend to
investigate the following interrelated six specific aims: 1) To identify all
constitutional ("germline") DNA variations across the entire SRD5A2 gene that
might contribute to predisposition to prostate cancer; 2) To determine the
relationship between each variant identified in Specific Aim 1 to prostate
cancer risk in for racial/ethnic populations: 4) To identify somatic mutations
in the SRD5A2 gene involved in prostate cancer progression; 5) To characterize
the biochemical properties of the somatic DNA genetic variants identified in
Specific aims 1 and 4 in an in vitro model system; 6) To determine the
contribution of somatic DNA genetic variants in the SRD5A2 gene to prostate
cancer progression within and across racial/ethnic groups. Therefore, we will
investigate the molecular basis of predisposition to prostate cancer and its
progression in a multidisciplinary study rooted in molecular epidemiology with
significant implications for presymptomatic identification of at-risk
individuals, targeted chemoprevention and improved treatment of this disease.
描述:(改编自研究者摘要)前列腺癌是
目前是美国男性中最常见的癌症。前列腺调节
细胞生长主要由雄激素控制,
双氢睾酮(DHT)。这种化合物是由雄性激素
睾丸激素由前列腺中编码的酶5-α还原酶
SRD 5A 2基因。前列腺癌的病因似乎包括
增加类固醇5-α还原酶活性,特别是在种族/民族之间
患前列腺癌的风险差异很大的人群,如高风险人群,
非裔美国人和低风险的亚洲人,两个极端的风险群体。我们
已经确定并表征了SRD 5A 2基因的遗传变异性,
美国的各种种族/族裔群体以及前列腺癌病例和
对照这些调查利用了洛杉矶的一个大型多种族队列,
洛杉矶和夏威夷。我们建议建立和扩大我们的研究SRD 5A 2
基因和前列腺癌的流行病学,遗传学和生化方法。它
我们的总体假设是,SRD 5A 2基因座的遗传变异在
在前列腺癌的易感性和进展中以及在
解释风险的种族/民族差异。为此,我们打算
研究以下六个相互关联的具体目标:1)确定所有
在整个SRD 5A 2基因上的构成(“种系”)DNA变异,
可能导致前列腺癌的易感性; 2)为了确定
特定目标1中确定的每个变体与前列腺
种族/民族人群的癌症风险:4)识别体细胞突变
在参与前列腺癌进展的SRD 5A 2基因中; 5)表征
鉴定的体细胞DNA遗传变异的生化特性,
具体目标1和4在体外模型系统中; 6)为了确定
SRD 5A 2基因体细胞DNA遗传变异对前列腺增生的作用
在种族/族裔群体内和跨种族/族裔群体的癌症进展。所以我们会
研究前列腺癌易感性的分子基础及其
一项植根于分子流行病学的多学科研究的进展,
症状前识别风险的重要意义
个体,有针对性的化学预防和改善这种疾病的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUERGEN K REICHARDT其他文献
JUERGEN K REICHARDT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUERGEN K REICHARDT', 18)}}的其他基金
VARIATION OF THE HSD17B3 GENE AND PROSTATE CANCER
HSD17B3 基因变异与前列腺癌
- 批准号:
2907324 - 财政年份:1999
- 资助金额:
$ 37.46万 - 项目类别:
VARIATION OF THE HSD17B3 GENE AND PROSTATE CANCER
HSD17B3 基因变异与前列腺癌
- 批准号:
6174364 - 财政年份:1999
- 资助金额:
$ 37.46万 - 项目类别:
5ALPHA REDUCTASE GENOTYPE, RACE AND PROSTATE CANCER RISK
5α 还原酶基因型、种族和前列腺癌风险
- 批准号:
2864704 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
5ALPHA REDUCTASE GENOTYPE, RACE AND PROSTATE CANCER RISK
5α 还原酶基因型、种族和前列腺癌风险
- 批准号:
2453044 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
5ALPHA REDUCTASE GENOTYPE, RACE AND PROSTATE CANCER RISK
5α 还原酶基因型、种族和前列腺癌风险
- 批准号:
2458206 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
5 α还原酶基因型,种族前列腺癌风险
- 批准号:
6512781 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
5ALPHA REDUCTASE GENOTYPE, RACE AND PROSTATE CANCER RISK
5α 还原酶基因型、种族和前列腺癌风险
- 批准号:
2112583 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
5ALPHA REDUCTASE GENOTYPE, RACE AND PROSTATE CANCER RISK
5α 还原酶基因型、种族和前列腺癌风险
- 批准号:
2614076 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
5 α还原酶基因型,种族前列腺癌风险
- 批准号:
6172801 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
5 α还原酶基因型,种族前列腺癌风险
- 批准号:
6376184 - 财政年份:1995
- 资助金额:
$ 37.46万 - 项目类别:
相似海外基金
Linking Social-Behavior Contextual Factors and Allostatic Load to Chronic Diseases in Diverse Asian Americans: A Socioecological Approach to Advancing Precision Medicine and Health Equity
将社会行为背景因素和稳态负荷与不同亚裔美国人的慢性病联系起来:推进精准医疗和健康公平的社会生态学方法
- 批准号:
10799170 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Collaborative Approach for Asian Americans, Native Hawaiians, and Pacific Islanders Research and Education (CARE) 2.0
亚裔美国人、夏威夷原住民和太平洋岛民研究与教育 (CARE) 2.0 合作方法
- 批准号:
10740342 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Asian Americans & Racism: Individual and Structural Experiences (ARISE)
亚裔美国人
- 批准号:
10900989 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Research Infrastructure for the study of Alzheimer's Disease and Alzheimer's Disease-related dementias in older Asian Americans
研究老年亚裔美国人阿尔茨海默病和阿尔茨海默病相关痴呆症的研究基础设施
- 批准号:
10730082 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Elucidating the high and heterogeneous risk of gestational diabetes among Asian Americans: an integrative approach of metabolomics, lifestyles, and social determinants
阐明亚裔美国人妊娠期糖尿病的高且异质性风险:代谢组学、生活方式和社会决定因素的综合方法
- 批准号:
10804399 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Disaggregating Asian Americans and Pacific Islanders to identify mechanisms of adolescent suicide risk: The role of school stressors, alcohol, sleep, and school/community contexts
分解亚裔美国人和太平洋岛民,以确定青少年自杀风险的机制:学校压力源、酒精、睡眠和学校/社区环境的作用
- 批准号:
10355313 - 财政年份:2022
- 资助金额:
$ 37.46万 - 项目类别:
Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health.
努力消除东南亚裔美国人肝癌护理差异:交通和其他健康的社会决定因素。
- 批准号:
10710050 - 财政年份:2022
- 资助金额:
$ 37.46万 - 项目类别:
Longitudinal Study of Early NAFLD Progression and the Gut Microbiome in Asian Americans, Native Hawaiians and Whites
亚裔美国人、夏威夷原住民和白人早期 NAFLD 进展和肠道微生物组的纵向研究
- 批准号:
10607981 - 财政年份:2022
- 资助金额:
$ 37.46万 - 项目类别:
Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health.
努力消除东南亚裔美国人肝癌护理差异:交通和其他健康的社会决定因素。
- 批准号:
10584157 - 财政年份:2022
- 资助金额:
$ 37.46万 - 项目类别:
Disaggregating Asian Americans and Pacific Islanders to identify mechanisms of adolescent suicide risk: The role of school stressors, alcohol, sleep, and school/community contexts
分解亚裔美国人和太平洋岛民,以确定青少年自杀风险的机制:学校压力源、酒精、睡眠和学校/社区环境的作用
- 批准号:
10544534 - 财政年份:2022
- 资助金额:
$ 37.46万 - 项目类别:














{{item.name}}会员




